comparing the efficacy and safety of intralesional acyclovir in two concentration in common warts

A comparative study of efficacy and safety of intralesional acyclovir 70mg/ml vs 100mg/ml in common warts including palmoplantar and periungual warts - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063057

Enrollment

200

Registered

2024-02-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: injection acyclovir: intralesional injection acyclovir 70mg/ml will be given at the interval of two weeks, maximum of 5 doses. Control Intervention1: injection acyclovir: intralesional

Eligibility

Inclusion criteria

Inclusion criteria: Warts <10 in number

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Children Hypersensitivity to acyclovir Patients with multiple warts ( >10) Patients who received any other treatment for warts at least 1 month before the study Patients on antiviral medication for other indications Not willing to participate or give consent

Design outcomes

Primary

Measure	Time frame
resolution of wartsTimepoint: period interval of 2 weeks, 4 weeks, 6 weeks and 8 weeks.	—

Secondary

Measure	Time frame
comparing efficacy & safety of intralesional acyclovir in concentration of 70mg per ml vs 100mg per mlTimepoint: period interval of 2 weeks 4weeks 6 weeks 8 weeks	—

Countries

India

Contacts

Public ContactDr Akanksha Sharma

Dr RPGMC KANGRA At TANDA

hoddermatology@gmail.com9418457647

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026